Human Ovarian Cancer Lysates
Pricing |
Normal Lysates: $125/100 ug |
Tumor Lysates: $175/100 ug |
Nor./Tum. set: $270.00 (10% off) |
Discounts |
2-8 Vials 10% |
9-20 Vials 15% |
>20 Vials 20% |
Histologic types of ovarian cancer include the following:
Serous cystomas - Serous benign cystadenomas, Serous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy), Serous cystadenocarcinomas.
Mucinous cystomas - Mucinous benign cystadenomas, Mucinous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy), Mucinous cystadenocarcinomas.
Endometrioid tumors (similar to adenocarcinomas in the endometrium) - Endometrioid benign cysts, Endometrioid tumors with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low malignant potential or borderline malignancy), Endometrioid adenocarcinomas.
Clear cell (mesonephroid) tumors - Benign clear cell tumors, Clear cell tumors with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low malignant potential or borderline malignancy), Clear cell cystadenocarcinomas.
Human Ovarian Cancer Lysates | ||||||
Catalog Number |
Diagnosis |
Grade |
Stage |
TNM |
Sex |
Age |
Ovarian carcinoma |
n/a |
n/a |
n/a |
F |
74 |
|
Ovarian serous cystadenoma |
n/a |
n/a |
n/a |
F |
38 |
|
Ovarian papillary adenocarcinoma |
n/a |
n/a |
n/a |
F |
53 |
|
Ovarian malignant granunosa cell |
n/a |
n/a |
n/a |
F |
54 |
|
Ovarian fibrosarcoma |
2 |
n/a |
n/a |
F |
49 |
|
Ovarian papillary adenocarcinoma |
n/a |
n/a |
n/a |
F |
73 |
|
Ovarian papillary adenocarcinoma |
n/a |
n/a |
n/a |
F |
52 |
|
Ovarian papillary cystadenocarcinoma |
n/a |
n/a |
n/a |
F |
53 |
|
Ovarian papillary adenocarcinoma |
n/a |
n/a |
n/a |
F |
41 |
|
Ovarian papillary cystadenocarcinoma |
n/a |
n/a |
n/a |
F |
32 |
|
Ovarian papillary cystadenocarcinoma |
n/a |
n/a |
n/a |
F |
50 |
|
Ovarian mucinous cystadenocarcinoma |
n/a |
IIIb |
n/a |
F |
54 |
|
Ovarian fibrosarcoma |
2 |
IIIc |
T2N1M0 |
F |
63 |
|
Sertoli-Leydig cell tumor |
2 |
II |
T1cNxMx |
F |
59 |
|
Ovarian papillary serous cystadenocarcinoma, moderately differentiated |
2 |
Ib |
T1bN0M0 |
F |
52 |
|
Ovarian papillary serous cystadenocarcinoma, moderately differentiated |
2 |
IIc, |
T2cN0M0 |
F |
43 |
|
Adenocarcinoma |
2 |
IIIb |
T3bN0M0 |
F |
54 |
|
Ovarian endometroid carcinoma, moderately differentiated |
2 |
Ia |
n/a |
F |
48 |
|
Ovarian endometroid carcinoma, moderately differentiated |
3 |
IIa |
T2N0M0 |
F |
49 |
|
Ovarian endometroid carcinoma, moderately differentiated |
2 |
IIIc |
T2bN1M0 |
F |
68 |
|
Ovarian endometroid carcinoma, moderately differentiated |
2 |
n/a |
n/a |
F |
61 |
|
Ovarian endometroid carcinoma, moderately differentiated |
2 |
n/a |
n/a |
F |
63 |
|
Ovarian clear cell carcinoma, moderately differentiated |
2 |
IIb |
T2N0M0 |
F |
38 |
|
Ovarian clear cell carcinoma, poorly differentiated |
3 |
Ia |
T1aN0M0 |
F |
39 |
|
Ovarian clear cell carcinoma, poorly differentiated |
3 |
III |
T3NxMx |
F |
54 |
|
Ovarian cystadenocarcinoma, moderately differentiated |
2 |
Ic |
T2N0Mx |
F |
52 |
|
Ovarian cystadenocarcinoma, moderately differentiated |
2 |
Ic |
T2N0Mx |
F |
35 | |
Ovarian cystadenocarcinoma, moderately differentiated |
2 |
III |
T2N0Mx |
F |
45 |
|
Ovarian cystadenocarcinoma, moderately differentiated |
2 |
Ia |
T2N0Mx |
F |
46 |
|
Ovarian anaplastic carcinoma, poorly differentiated |
3 |
Ic |
T1N0Mx |
F |
44 |
|
Ovarian dysgerminoma, poorly differentiated. |
2 |
III |
T3NxM1 |
F |
17 |
|
Ovarian dysgerminoma, poorly differentiated |
2 |
Ia |
T1N0Mx |
F |
17 |
|
Ovarian fibrosarcoma, moderately differentiated |
2 |
II |
T2N0M0 |
F |
76 |
|
Ovarian Sertoli-Leydig cell tumor, poorly differentiated |
3 |
n/a |
n/a |
F |
63 |
|
Ovarian adenocarcinoma, moderately differentiated. |
2 |
IIa |
T2N0Mx |
F |
50 |
|
Ovarian adenocarcinoma, moderately differentiated. |
2 |
IIIa |
T3aN0M0 |
F |
40 |
|
Ovarian adenocarcinoma, poorly differentiated |
3 |
IIc |
T2cN0M0 |
F |
15 |
|
Ovarian adenocarcinoma, poorly differentiated |
3 |
IIIc |
T2aN1M0 |
F |
44 |
|
Ovarian adenocarcinoma, poorly differentiated |
3 |
IIIc |
n/a |
F |
50 |
|
Ovarian adenocarcinoma, moderately differentiated |
3 |
II, |
T2N0M0 |
F |
44 |
|
Ovarian serous cystadenocarcinoma, moderately differentiated |
2 |
Ib |
T1N0Mx |
F |
47 |
|
Ovarian serous cystadenocarcinoma, poorly differentiated |
3 |
n/a |
n/a |
F |
43 |
|
Ovarian granulose cell carcinoma, moderately differentiated |
2 |
IIIa |
T3aN0M0 |
F |
69 |
|
Ovarian granulose cell carcinoma, moderately differentiated. |
2 |
n/a |
n/a |
F |
45 |
|
Ovarian granulosa cell carcinoma, poorly differentiated |
2 |
n/a |
T1aN0M0 |
F |
75 |
|
Ovarian signet ring cell carcinoma, poorly differentiated |
3 |
n/a |
n/a |
F |
35 |
|
Ovarian mature teratoma, poorly differentiated. |
n/a |
n/a |
n/a |
F |
70 |
|
Ovarian yolk sac tumor, poorly differentiated. |
3 |
Ic |
n/a |
F |
16 |
References:
Silverberg SG, Major FJ, Blessing JA, et al.: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9 (1): 1-19, 1990.